Carcinoembryonic antigen (CEA) has been used as a serum biomarker for CRC diagnosis and prognosis for several years, and its significance and usefulness in clinical applications have been reported in many studies [8, 9]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.